| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.1701568 |
| P953 | full work available at URL | https://syndication.highwire.org/content/doi/10.1126/science.1701568 |
| P698 | PubMed publication ID | 1701568 |
| P2093 | author name string | J. Adams | |
| J. C. Wu | |||
| K. D. Hargrave | |||
| V. J. Merluzzi | |||
| C. K. Shih | |||
| K. Grozinger | |||
| S. Hattox | |||
| K. Eckner | |||
| M. Labadia | |||
| M. Skoog | |||
| P2860 | cites work | 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro | Q24609215 |
| Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 | ||
| Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives | Q28323202 | ||
| HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy | Q28339571 | ||
| Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability | Q29617252 | ||
| The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | Q29620805 | ||
| Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. | Q30355613 | ||
| The enzymatic termination of polydeoxynucleotides by 2',3'-dideoxyadenosine triphosphate | Q36448864 | ||
| Evolution of type C viral genes: origin of feline leukemia virus | Q39352098 | ||
| Kinetics of pharmacologic response | Q40245591 | ||
| Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities | Q41257221 | ||
| Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes | Q42822749 | ||
| Quantitation of human immunodeficiency virus type 1 in the blood of infected persons | Q45844274 | ||
| Unexpectedly high levels of HIV-1 RNA and protein synthesis in a cytocidal infection. | Q55242378 | ||
| A detailed model of reverse transcription and tests of crucial aspects | Q66971643 | ||
| Complement-fixation test for feline leukemia and sarcoma viruses (the COCAL test) | Q70566225 | ||
| P433 | issue | 4986 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HIV | Q15787 |
| Reverse Transcriptase Inhibitors | Q95589949 | ||
| P304 | page(s) | 1411-3 | |
| P577 | publication date | 1990-12-07 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor | |
| Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor | |||
| P478 | volume | 250 |
| Q40733824 | "Senseless" antiviral polyribonucleotides: poly (1-propargylinosinic acid). |
| Q28378859 | (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants [...] |
| Q28379406 | 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity |
| Q28316183 | 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri |
| Q28342745 | 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors |
| Q40983898 | 3-(5-Dimethylamino-1-naphthalenesulphonyl)-2-(3-pyridyl)thiazolidine (YHI-1) selectively inhibits human immunodeficiency virus type 1. |
| Q39632642 | 7,8‐Secolignans from Schisandra wilsoniana and Their Anti‐HIV‐1 Activities |
| Q42537169 | A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine |
| Q71802904 | A fight to the death |
| Q57012728 | A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors |
| Q57012695 | A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors. 2. The relationship between alignment solutions obtained from conformationally rigid and flexible matching |
| Q28368028 | A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors |
| Q28368038 | A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors |
| Q54114811 | A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. |
| Q28659108 | A reverse transcriptase-dependent mechanism is essential for murine preimplantation development |
| Q36263207 | A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy. |
| Q33514519 | A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons |
| Q39531429 | A time-of-drug addition approach to target identification of antiviral compounds |
| Q37589125 | A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines |
| Q28368053 | Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication |
| Q34701036 | Advances in QSAR studies of HIV-1 reverse transcriptase inhibitors. |
| Q40609666 | An autoimmune disease prevented by anti-retroviral drugs |
| Q44060918 | An evaluation of antiretroviral therapy associated with alpha-tocopherol supplementation in HIV-infected patients |
| Q41346811 | Analysis of inhibition of retroviral reverse transcriptase |
| Q28368003 | Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase |
| Q33957283 | Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors |
| Q28367667 | Anti-(human immunodeficiency virus) activity of polyoxotungstates and their inhibition of human immunodeficiency virus reverse transcriptase |
| Q35341682 | Anti-AIDS drug development: challenges and strategies |
| Q28378745 | Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase |
| Q71828771 | Antiretroviral therapy |
| Q41682612 | Antiretroviral therapy in the pregnant woman |
| Q35322871 | Antiretroviral therapy: reverse transcriptase inhibition |
| Q40055204 | Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses |
| Q46576605 | Antiviral activity of 4-benzyl pyridinone derivatives as HIV-1 reverse transcriptase inhibitors |
| Q40874319 | Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. |
| Q35366050 | Antiviral therapy for human immunodeficiency virus infections |
| Q40487963 | Antiviral therapy in human immunodeficiency virus infections. Current status (Part II). |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q40211088 | Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 1). |
| Q28323825 | BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine |
| Q42542425 | Baicalin, an inhibitor of HIV-1 production in vitro |
| Q36634319 | Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate |
| Q35563298 | Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design |
| Q28367552 | Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro |
| Q35122165 | Blocking premature reverse transcription fails to rescue the HIV-1 nucleocapsid-mutant replication defect |
| Q77654970 | Candidate antiretroviral agents for use in postexposure prophylaxis |
| Q64028382 | Catalytic Asymmetric Reactions Involving the Seven-Membered Cyclic Imine Moieties Present in Dibenzo[b ,f ][1,4]oxazepines |
| Q35785323 | Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors |
| Q28378595 | Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217 |
| Q43525800 | Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase |
| Q28379510 | Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase |
| Q42740741 | Chemical crosslinking of the subunits of HIV-1 reverse transcriptase. |
| Q45858732 | Chemotherapy of the acquired immune deficiency syndrome (AIDS): Non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase |
| Q28324145 | Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors |
| Q37859395 | Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations |
| Q35842270 | Clinical utility of current NNRTIs and perspectives of new agents in this class under development |
| Q57947921 | Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptase |
| Q31114765 | Closing of the fingers domain generates motor forces in the HIV reverse transcriptase |
| Q42537093 | Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors |
| Q28367556 | Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor |
| Q30400060 | Combinatorial approaches to the prevention and treatment of HIV-1 infection |
| Q39645737 | Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors |
| Q28368052 | Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors |
| Q31454187 | Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. |
| Q33898904 | Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams |
| Q42716799 | Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles |
| Q43979142 | Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations |
| Q43478930 | Conformational analysis of the HIV-1 virus reverse transcriptase nonnucleoside inhibitors: TIBO and nevirapine. |
| Q45756374 | Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor |
| Q36429712 | Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV. |
| Q59096959 | Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro |
| Q35174403 | Correlations Between theIn VitroandIn VivoActivity of Anti-HIV Agents: Implications for Future Drug Deyelopment |
| Q29620616 | Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA |
| Q37637676 | Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution |
| Q36558109 | Current developments in HIV chemotherapy |
| Q26852626 | Current perspectives on HIV-1 antiretroviral drug resistance |
| Q36548703 | Current status of antiretroviral therapy |
| Q37247615 | Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals |
| Q40503600 | De novo RNA synthesis and homology modeling of the classical swine fever virus RNA polymerase |
| Q38346006 | Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. |
| Q40246588 | Design, synthesis, biological evaluation, and molecular modeling studies of TIBO-like cyclic sulfones as non-nucleoside HIV-1 reverse transcriptase inhibitors |
| Q35174341 | Development of Inhibitors of Reverse Transcriptase and Protease as Therapeutics Against HIV Infection |
| Q37789224 | Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41 |
| Q41243158 | Development of nonnucleoside HIV reverse transcriptase inhibitors |
| Q35123292 | Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections |
| Q45768310 | Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro |
| Q33209407 | Diversity-oriented solid-phase synthesis and biological evaluation of oligonucleotide hairpins as HIV-1 RT RNase H inhibitors |
| Q44195803 | Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase |
| Q33937534 | Domain structure of the human immunodeficiency virus reverse transcriptase |
| Q42738742 | Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers |
| Q42198524 | Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition |
| Q40399390 | Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor |
| Q44620203 | Efficacy and Durability of Nevirapine in Antiretroviral Drug Naïve Patients |
| Q74601842 | Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial |
| Q46335954 | Efficient TCT-catalyzed synthesis of 1,5-benzodiazepine derivatives under mild conditions. |
| Q34594711 | Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. |
| Q38290579 | Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates |
| Q67466275 | Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843 |
| Q45789645 | Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138→Arg and Tyr-188→His mutations |
| Q43723233 | Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues |
| Q40647841 | Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation |
| Q62270403 | Facile preparation of 9-H-pyrimido [4,5-b] [1,4] diazepine derivatives from 4,5-diaminopyrimidines and ethyl pyruvate |
| Q73569162 | Factors affecting the dimerization of the p66 form of HIV-1 reverse transcriptase |
| Q26764925 | Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors |
| Q60304374 | HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1 |
| Q54233451 | HIV and multidrug resistance |
| Q39806672 | HIV inactivation by cross-linking of photo-labeled anti-retroviral compounds with HIV reverse transcriptase |
| Q40393212 | HIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring |
| Q40486578 | HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase |
| Q27729427 | High resolution structures of HIV-1 RT from four RT-inhibitor complexes |
| Q33796791 | High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1 |
| Q45789678 | High-performance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus type-1 |
| Q28379523 | Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates |
| Q34026086 | Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors |
| Q28324214 | Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture |
| Q39634357 | Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity |
| Q47613826 | Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors |
| Q28379002 | Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus |
| Q28316336 | Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors |
| Q40983879 | Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation |
| Q35375912 | In search of a selective antiviral chemotherapy. |
| Q28486262 | In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis |
| Q38089836 | Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: docking and 3D QSAR studies |
| Q46880909 | Inhibition of HIV-1 and M-MLV reverse transcriptases by a major polyphenol (3,4,5 tri-O-galloylquinic acid) present in the leaves of the South African resurrection plant, Myrothamnus flabellifolia |
| Q33582517 | Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides |
| Q38313099 | Inhibition of HIV-1 reverse transcriptase by defined template/primer DNA oligonucleotides: effect of template length and binding characteristics |
| Q38322556 | Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives. Potency, binding characteristics, and effect of template sequence |
| Q37470888 | Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells. |
| Q37072072 | Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor |
| Q28367369 | Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans |
| Q42275289 | Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non‐nucleoside inhibitors |
| Q43000887 | Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases |
| Q34050684 | Inhibitors of HIV-1 reverse transcriptase |
| Q74126716 | Inhibitory potency of R-region specific antisense oligonucleotides against in vitro DNA polymerization and template-switching reactions catalysed by HIV-1 reverse transcriptase |
| Q39254865 | Interactions between 2,4-bis-pteridine-1,5-benzodiazepine and group 12 dihalides: synthesis, spectral and XRD structural studies and theoretical calculations. |
| Q30456752 | Investigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations |
| Q36499463 | Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors |
| Q35854030 | Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo |
| Q45859635 | Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, R82150 |
| Q28316334 | L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro |
| Q48659826 | LINE-1 retrotransposon copies are amplified during murine early embryo development |
| Q27729428 | Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors |
| Q55063317 | Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. |
| Q38298830 | Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase |
| Q35122784 | Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription |
| Q40793195 | Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro |
| Q34034000 | Mitochondrial and Plasma Membrane Citrate Transporters: Discovery of Selective Inhibitors and Application to Structure/Function Analysis |
| Q59359510 | Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review |
| Q40446517 | Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds |
| Q24794051 | Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen |
| Q54549089 | Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT. |
| Q34798628 | Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis |
| Q34294871 | N-Cyclo-hexyl-5H,7H-13,15-dimethyl-9-nitro-5-oxophenanthrido[4,4a,5-bc][1,4]benzoxazepine-7-carboxamide |
| Q39203403 | N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase. |
| Q43543896 | N2-benzyloxycarbonylguan-9-yl acetic acid derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors with decreased loss of potency against common drug-resistance mutations |
| Q36221687 | NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities |
| Q43759268 | Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment. |
| Q38297932 | Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase |
| Q40072847 | Nevirapine induced mitochondrial dysfunction in HepG2 cells. |
| Q39934856 | Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. |
| Q33850152 | Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation |
| Q43956445 | Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. |
| Q28367526 | Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy |
| Q34055828 | Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection |
| Q34078483 | Nevirapine: pharmacokinetic considerations in children and pregnant women |
| Q40390744 | New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors |
| Q28367654 | New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs |
| Q44548859 | Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate |
| Q33813305 | Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom |
| Q36297904 | Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase |
| Q28324100 | Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication |
| Q42911025 | Novel Isocyanide-Based One-Pot Multicomponent Syntheses of Tetrahydrobenzo[b][1,4]oxazepine and Malonamide Derivatives |
| Q41153307 | Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity. |
| Q36632128 | Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase |
| Q37338985 | Other inhibitors of viral enzymes and functions |
| Q35372072 | Pediatric human immunodeficiency virus infection. |
| Q33631716 | Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection |
| Q47359813 | Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection |
| Q35808226 | Pharmacokinetics of nevirapine: initial single-rising-dose study in humans |
| Q41727754 | Pharmacophores in drug design and discovery |
| Q27621483 | Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses |
| Q36366438 | Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. |
| Q28368005 | Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase |
| Q28320362 | Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event |
| Q28378831 | Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives |
| Q28469069 | Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol |
| Q28378825 | Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication |
| Q28367573 | Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro |
| Q33209838 | Predicting anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones: computational approach using reformed eccentric connectivity index |
| Q40486948 | Present Status and Future Prospects for HIV Therapies |
| Q38997200 | Process Chemistry in Antiviral Research |
| Q52845326 | Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. |
| Q54152447 | Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets |
| Q28323976 | Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity |
| Q28376481 | Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 |
| Q33681664 | Recent advances in antiviral therapy |
| Q37776443 | Recent progress of isocyanide-based multicomponent reactions in Iran |
| Q44095311 | Reconstitution and properties of homologous and chimeric HIV-1.HIV-2 p66.p51 reverse transcriptase |
| Q28378547 | Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents |
| Q28368381 | Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines |
| Q22242815 | Reverse transcription of the HIV-1 pandemic |
| Q34187649 | Role of tipranavir in treatment of patients with multidrug-resistant HIV |
| Q28379544 | S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1 |
| Q107344282 | SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2 |
| Q50129893 | SJP-L-5 inhibits HIV-1 polypurine tract primed plus-strand DNA elongation, indicating viral DNA synthesis initiation at multiple sites under drug pressure |
| Q33978490 | Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. |
| Q41643977 | Significant Anti-HIV Activity of New Modified Poly Anionic Polymersin vitro |
| Q42275864 | Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s |
| Q28342783 | Specific HIV-1 reverse transcriptase inhibitors |
| Q28368032 | Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors |
| Q40695351 | Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate |
| Q40504294 | Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template |
| Q34305893 | Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E |
| Q35930774 | Strategies in the treatment of AIDS and related diseases: the lessons of cancer chemotherapy |
| Q27661750 | Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors |
| Q37099790 | Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase |
| Q56531878 | Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitors |
| Q42539141 | Structural determination of metabolites of S-1153, a new, potent, non-nucleoside, anti-HIV agent in rat liver microsomes |
| Q27729437 | Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors |
| Q30342229 | Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. |
| Q27729431 | Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution |
| Q44363800 | Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations |
| Q27729365 | Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1 |
| Q28378796 | Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide |
| Q27640501 | Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation |
| Q37546137 | Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase |
| Q28367590 | Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors |
| Q45388175 | Synthesis and HIV-1 RT inhibitory action of novel (4/6-substituted benzo[d]thiazol -2-yl)thiazolidin-4-ones. Divergence from the non-competitive inhibition mechanism |
| Q28378262 | Synthesis and HIV-1 inhibitory properties of new tetrahydrobenzoquinazolinedione and tetrahydrobenzocycloheptenuracil derivatives and of their thioxo analogues |
| Q28369722 | Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors |
| Q44564965 | Synthesis and anti-HIV activity of some heterodimers [NRTI]-glycyl-succinyl-[trovirdine analogue] of known HIV-1 reverse transcriptase inhibitors |
| Q28374370 | Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors |
| Q59417642 | Synthesis of [1-[3′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-arabino- and β-d-ribofuranosyl]cytosine]-2′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T |
| Q52611710 | Synthesis of a novel fused pyrrolodiazepine-based library with anti-cancer activity. |
| Q40986686 | Synthesis of aryl semicarbazone of 4-aminoacetophenone and their anti-HIV activity. |
| Q95797309 | Synthesis of some new biologically active bis-(thiadiazolotriazines) and bis-(thiadiazolotriazinyl) alkanes |
| Q34674575 | Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme |
| Q33377976 | TIBO R82913, A New HIV-1 Inhibiting Agent, Does Not Inhibit Hematopoietic Progenitor Cells |
| Q90274970 | The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic |
| Q28367759 | The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase |
| Q38351813 | The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer |
| Q51558445 | The base-promoted synthesis of multisubstituted benzo[b][1,4]oxazepines. |
| Q71562806 | The eighth mystery of acquired immune deficiency syndrome and the "Trojan horse' mechanism |
| Q34102246 | The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors |
| Q40662335 | The molecular biology of HIV. Insights into pathogenesis and targets for therapy. |
| Q42278148 | The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase |
| Q54123440 | The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. |
| Q27732214 | The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design |
| Q41971165 | The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor |
| Q33976004 | The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. |
| Q51577584 | Theoretical and experimental (15)N NMR study of enamine-imine tautomerism of 4-trifluoromethyl[b]benzo-1,4-diazepine system. |
| Q41546154 | Thiazolobenzimidazole: Biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor |
| Q73390518 | Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis |
| Q36651931 | Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. |
| Q51483647 | Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). |
| Q41864362 | Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine |
| Q28368034 | U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication |
| Q27735940 | Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor |
| Q54247387 | Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy |
| Q29547908 | Viral dynamics in human immunodeficiency virus type 1 infection |
| Q28323994 | Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors |
| Q28367531 | Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase |
| Q28478130 | Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development |
| Q41879645 | Xenotropic murine leukemia virus-related virus is susceptible to AZT. |
| Q28318473 | [2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1 |
| Q28368045 | Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analo |
Search more.